Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QAX576 in Asthma Patients [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reporting safety, tolerability, pharmacokinetics and pharmacodynamics of QAX576 in asthma patients across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• QAX576

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Asthma | Phase 1, Phase 2 | Status: COMPLETED